GlassScriptPhysician profile
Sarah Jane Krepps
NPI 1588276034
$1,768.61
in general payments reported to CMS, 2019-2025
24 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $260 · 2024: $1,073 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $352.08 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $297.77 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $243.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $137.38 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.41 | 2024-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $71.12 | 2024 | Voquezna |
| Amgen INC. | $68.98 | 2024-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $65.66 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $56.26 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $48.20 | 2023-2025 | |
| Glaxosmithkline, LLC. | $41.09 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Eisai INC. | $38.61 | 2024-2025 | |
| Protega Pharmaceutials INC | $35.18 | 2024 | Roxybond |
| Novartis Pharmaceuticals Corporation | $33.26 | 2025 | |
| Ardelyx, INC. | $31.89 | 2025 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $21.18 | 2024 | Senza |
| Axsome Therapeutics, INC. | $20.51 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $20.35 | 2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.41 | 2025 | Xifaxan |
| Scilex Pharmaceuticals INC. | $16.96 | 2024 | |
| Corcept Therapeutics | $16.46 | 2023 | Korlym |
| Amneal Pharmaceuticals LLC | $15.62 | 2024 | Unithroid |
| Exact Sciences Corporation | $13.89 | 2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $12.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Krepps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.